Millennium Submits sNDA for Long-Term Overall Survival Results of Velcade in Previously Untreated Multiple Myeloma

Millennium; a Takeda Oncology Company announced the submission of a supplemental new drug application with the U.S. Food and Drug Administration for Velcade (bortezomib) for injection to add overall survival (OS) data after a five-year follow up to the product label.
SunHearald